← board
CLSD
distress 5/10 · elevated risk$0.250%today-98% from 52w high
Revenue
pre-revenue
Liquidity
$17M
Runway
0.8 yrs
Shares 1y
—
Price & events
-78.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+126.4%
1M
-5.8%
3M
-78.3%
6M
-95.3%
1Y
—
2Y
—
5Y
-98.3%
All
Overview
- Volume
- 0
- 52 Week Range
- $0.01 – $13.27
- Float Shares
- 4.54M
- Short %
- 2.74%
- % Held by Insiders
- 12.88%
- % Held by Institutions
- 13.68%
- Beta
- 1.79
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $60 (+23996% upside) · 2 analysts
- 2025-11-18NeedhamHold
- 2025-07-18HC Wainwright & Co.Buy → Neutral
- 2025-07-18Chardan CapitalBuy → Neutral
- 2025-07-17NeedhamBuy → Hold
- 2025-05-23HC Wainwright & Co.Buy
- 2025-05-16JMP SecuritiesMarket Outperform
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.